Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 Oncogenes

NCT03868423 is registered in ClinicalTrials.gov with Sameek Roychowdhury as lead sponsor.

NCT NCT03868423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03868423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 Oncogenes
Lead sponsor
Sameek Roychowdhury
Phase
Phase 2
Overall status
Withdrawn
Start date
March 20, 2019
Completion date
December 30, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant neoplasm, alk fusion protein expression, alk gene amplification, alk gene mutation, locally advanced malignant solid neoplasm, metastatic malignant neoplasm in the brain, metastatic malignant neoplasm in the central nervous system, metastatic malignant solid neoplasm, ros1 fusion positive, ros1 gene amplification, ros1 gene mutation